RCMI Coordinating Center (RCMI CC) Header Logo

Connection

George S.N. Hui to Antibodies, Protozoan

This is a "connection" page, showing publications George S.N. Hui has written about Antibodies, Protozoan.
Connection Strength

2.217
  1. Pusic K, Xu H, Stridiron A, Aguilar Z, Wang A, Hui G. Blood stage merozoite surface protein conjugated to nanoparticles induce potent parasite inhibitory antibodies. Vaccine. 2011 Nov 08; 29(48):8898-908.
    View in: PubMed
    Score: 0.393
  2. Hui G, Choe D, Hashimoto C. Biological activities of anti-merozoite surface protein-1 antibodies induced by adjuvant-assisted immunizations in mice with different immune gene knockouts. Clin Vaccine Immunol. 2008 Aug; 15(8):1145-50.
    View in: PubMed
    Score: 0.313
  3. Hui GS, Hashimoto CN. Adjuvant formulations possess differing efficacy in the potentiation of antibody and cell mediated responses to a human malaria vaccine under selective immune genes knockout environment. Int Immunopharmacol. 2008 Jul; 8(7):1012-22.
    View in: PubMed
    Score: 0.309
  4. Hui G, Hashimoto C. The requirement of CD80, CD86, and ICAM-1 on the ability of adjuvant formulations to potentiate antibody responses to a Plasmodium falciparum blood-stage vaccine. Vaccine. 2007 Dec 12; 25(51):8549-56.
    View in: PubMed
    Score: 0.300
  5. Nagata M, Wong T, Clements D, Hui G. Plasmodium falciparum: immunization with MSP1-42 induced non-inhibitory antibodies that have no blocking activities but enhanced the potency of inhibitory anti-MSP1-42 antibodies. Exp Parasitol. 2007 Apr; 115(4):403-8.
    View in: PubMed
    Score: 0.281
  6. Hui G, Hashimoto C. Plasmodium falciparum anti-MSP1-19 antibodies induced by MSP1-42 and MSP1-19 based vaccines differed in specificity and parasite growth inhibition in terms of recognition of conserved versus variant epitopes. Vaccine. 2007 Jan 15; 25(5):948-56.
    View in: PubMed
    Score: 0.278
  7. Pusic K, Clements D, Kobuch S, Hui G. Antibody and T cell responses in reciprocal prime-boost studies with full-length and truncated merozoite surface protein 1-42 vaccines. PLoS One. 2013; 8(9):e75939.
    View in: PubMed
    Score: 0.113
  8. Hui G, Hashimoto C. Interleukin-6 has differential influence on the ability of adjuvant formulations to potentiate antibody responses to a Plasmodium falciparum blood-stage vaccine. Vaccine. 2007 Sep 04; 25(36):6598-603.
    View in: PubMed
    Score: 0.074
  9. Yuen D, Leung WH, Cheung R, Hashimoto C, Ng SF, Ho W, Hui G. Antigenicity and immunogenicity of the N-terminal 33-kDa processing fragment of the Plasmodium falciparum merozoite surface protein 1, MSP1: implications for vaccine development. Vaccine. 2007 Jan 05; 25(3):490-9.
    View in: PubMed
    Score: 0.069
  10. Hui GS, Hashimoto CN. Pathways for potentiation of immunogenicity during adjuvant-assisted immunizations with Plasmodium falciparum major merozoite surface protein 1. Infect Immun. 1998 Nov; 66(11):5329-36.
    View in: PubMed
    Score: 0.040
  11. Hui GS, Nikaido C, Hashiro C, Kaslow DC, Collins WE. Dominance of conserved B-cell epitopes of the Plasmodium falciparum merozoite surface protein, MSP1, in blood-stage infections of naive Aotus monkeys. Infect Immun. 1996 May; 64(5):1502-9.
    View in: PubMed
    Score: 0.034
  12. Pang AL, Hashimoto CN, Tam LQ, Meng ZQ, Hui GS, Ho WK. In vivo expression and immunological studies of the 42-kilodalton carboxyl-terminal processing fragment of Plasmodium falciparum merozoite surface protein 1 in the baculovirus-silkworm system. Infect Immun. 2002 Jun; 70(6):2772-9.
    View in: PubMed
    Score: 0.013
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support